PLANTATION, Florida and HOUSTON, Texas, Oct. 8, 2024 /PRNewswire/ --
GBI Biomanufacturing, a leading Contract Development and Manufacturing Organization (CDMO), and
Allterum Therapeutics, a
Fannin-Founded Company, are pleased to announce a manufacturing partnership to advance Allterum's lead candidate
4A10 into clinic.
4A10 is a monoclonal antibody (mAb) targeting CD127, a receptor expressed by a broad variety of cancers.
With this collaboration, GBI will leverage their extensive expertise in manufacturing complex biologics to ensure the high-quality production of 4A10 for Phase 1/2a clinical trials. Allterum's initial trial will focus on patients who have acute lymphoblastic leukemia (ALL), with subsequent expansion to trials in patients with other CD127-expressing hematological malignancies, including lymphomas and acute myeloid leukemia.